[{"id":"31454fa9-6161-4186-9e06-a56674386923","acronym":"OVARD","url":"https://clinicaltrials.gov/study/NCT05918042","created_at":"2023-06-26T14:09:05.501Z","updated_at":"2024-07-02T16:35:02.427Z","phase":"","brief_title":"A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation","source_id_and_acronym":"NCT05918042 - OVARD","lead_sponsor":"AstraZeneca","biomarkers":" HRD","pipe":" | ","alterations":" HRD • HRD + BRCA wild-type","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • HRD + BRCA wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 01/25/2025","primary_completion_date":" 01/25/2025","study_txt":" Completion: 01/25/2025","study_completion_date":" 01/25/2025","last_update_posted":"2024-05-21"}]